Nemec Sarah 4

What Happened

• Sarah Nemec, Senior Vice President, Finance and PAO of Bolt Biotherapeutics, received a grant (derivative) for 8,000 shares on 2026-01-28 (no cash price listed) and earlier purchased 125 shares on 2025-12-05 in an open-market/ESPP transaction at $4.61 per share (≈ $576 total). The 8,000-share grant is an option (derivative) that is subject to vesting rather than immediate unrestricted shares — it does not represent an immediate sale.

Key Details

• Purchase: 125 shares on 2025-12-05 at $4.61 per share (total ≈ $576). Footnote: acquired under the issuer’s Employee Stock Purchase Plan (ESPP), exempt under Rule 16b-3(c).
• Grant/Award: 8,000 shares reported on 2026-01-28 as a derivative (no cash price); footnote specifies this is an option that will vest 1/36th per month of continuous service following Jan 1, 2026.
• Shares owned after the transactions: not specified in the provided data.
• Filing: Form 4 filed 2026-02-04 reporting the 2026-01-28 grant (and the 2025-12-05 purchase). This filing appears late relative to the typical 2-business-day Form 4 requirement.

Context

• The 8,000-share entry is an option grant (derivative) with a monthly vesting schedule — it does not mean Nemec sold shares or received immediately-tradable stock. The 125-share ESPP purchase is a small insider buy (routine) and is often viewed by investors as a modest bullish signal, though it’s common for employees to participate in ESPPs.